Free tool
FAERS Monitor: Vykat Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216665 or its brand name (Vykat Xr, Diazoxide Choline). Reports on generic versions are filed under their own applications.
Reports
690
Serious
134
19% of reports
Hospitalization
97
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- oedema peripheral135
- peripheral swelling98
- weight increased97
- drug ineffective95
- blood glucose increased84
- fluid retention75
- oedema59
- hair growth abnormal48
- hyperglycaemia45
- hyperphagia45
- abnormal behaviour44
- hypertrichosis37
- aggression36
- dyspnoea33
- fatigue27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 172 |
| 2026 | 518 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,469 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypertrichosisSignal | 37 | 621.0 | 452.4 | 21,844 |
| hyperphagiaSignal | 45 | 347.9 | 261.8 | 15,051 |
| hair growth abnormalSignal | 48 | 212.9 | 161.9 | 9,846 |
| fluid retentionSignal | 75 | 45.0 | 36.3 | 3,187 |
| hyperglycaemiaSignal | 45 | 37.7 | 28.4 | 1,572 |
| abnormal behaviourSignal | 44 | 33.9 | 25.5 | 1,373 |
| oedema peripheralSignal | 135 | 33.8 | 29.0 | 4,284 |
| oedemaSignal | 59 | 33.2 | 26.0 | 1,813 |
| aggressionSignal | 36 | 21.9 | 16.0 | 700 |
| peripheral swellingSignal | 98 | 19.4 | 16.2 | 1,704 |
| blood glucose increasedSignal | 84 | 13.6 | 11.1 | 976 |
| weight increasedSignal | 97 | 13.2 | 11.0 | 1,094 |
| drug ineffectiveSignal | 95 | 2.2 | 1.8 | 65 |
| dyspnoea | 33 | 1.8 | 1.3 | 11 |
| fatigue | 27 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.